newsTakeda will acquire Nimbus Therapeutics for $4 billion and gain…
14 December 2022 | By Catherine Eckford (European Pharmaceutical Review)
Takeda will acquire Nimbus Therapeutics for $4 billion and gain rights to its allosteric TYK2 Inhibitor to address multiple immune-mediated diseases.